G
Gihad Dargazanli
Researcher at Centre national de la recherche scientifique
Publications - 22
Citations - 590
Gihad Dargazanli is an academic researcher from Centre national de la recherche scientifique. The author has contributed to research in topics: Alkoxy group & Alkyl. The author has an hindex of 9, co-authored 21 publications receiving 532 citations.
Papers
More filters
Journal ArticleDOI
Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic.
Ronan Depoortère,Gihad Dargazanli,Genevieve Estenne-Bouhtou,Annick Coste,Christophe Lanneau,C. Desvignes,Martine Poncelet,Michel Heaulme,Vincent Santucci,Michel Decobert,Annie Cudennec,Carolle Voltz,Denis Boulay,Jean Paul Terranova,Jeanne Stemmelin,Pierre Roger,Benoit Marabout,Mireille Sevrin,Xavier Vigé,Bruno Biton,Régis Steinberg,Dominique Françon,R. Alonso,Patrick Avenet,F. Oury-Donat,Ghislaine Perrault,Guy Griebel,Pascal George,Philippe Soubrie,Bernard Scatton +29 more
TL;DR: SSR504734 is a potent and selective GlyT1 inhibitor, exhibiting activity in schizophrenia, anxiety and depression models, and is expected to be efficacious not only against positive but also negative symptoms, cognitive deficits, and comorbid depression/anxiety states.
Journal ArticleDOI
Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia☆
Denis Boulay,Philippe Pichat,Gihad Dargazanli,Genevieve Estenne-Bouhtou,Jean Paul Terranova,Nancy Rogacki,Jeanne Stemmelin,Annick Coste,Christophe Lanneau,C. Desvignes,Caroline Cohen,R. Alonso,Xavier Vigé,Bruno Biton,Régis Steinberg,Mireille Sevrin,F. Oury-Donat,Pascal George,Olivier Bergis,Guy Griebel,Patrick Avenet,Bernard Scatton +21 more
TL;DR: Findings suggest that SSR103800 may have a therapeutic potential in the management of the core symptoms of schizophrenia and comorbid depression states.
Journal ArticleDOI
The selective reversible FAAH inhibitor, SSR411298, restores the development of maladaptive behaviors to acute and chronic stress in rodents.
Guy Griebel,Jeanne Stemmelin,Mati Lopez-Grancha,Valérie Fauchey,Franck Slowinski,Philippe Pichat,Gihad Dargazanli,Ahmed Abouabdellah,Caroline Cohen,Olivier Bergis +9 more
TL;DR: Results from experiments in models of depression showed that SSR411298 produced robust antidepressant-like activity in the rat forced-swimming test and in the mouse chronic mild stress model, restoring notably the development of inadequate coping responses to chronic stress.
Patent
Derivatives of n-[phenyl(alkylpiperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics
TL;DR: In this article, the use of compounds having general formula (I) relates to compounds having generic formula (II) wherein: R represents a hydrogen atom, an alkyl group, a cycloalkyl group, cyclo-alkyl groups, a phenylalkyl, alkenyl, or an alkynyl group; X represents a halogen atom or one or more halogen atoms and trifluoromethyl.
Patent
N-[phenyl (piperidin-2-yl) methyl]benzamide derivatives, preparation thereof, and use thereof in therapy
TL;DR: In this paper, compounds of general formula (I) were defined, where R represents a hydrogen atom, X represents one or several substituents selected among halogen atoms and trifluoromethyl, alkyl, and alkoxy groups.